CASI CASI Pharmaceuticals
- 3.2400
- -0.2200-6.36%
- 3.2500
- +0.0100+0.31%
CASI Pharmaceuticals News
Sector Update: Health Care Stocks Advance in Afternoon Trading
Health care stocks were higher Wednesday afternoon, with the NYSE Health Care Index adding 1.1% and the Health Care Select Sector SPDR Fund (XLV) rising 1.3%. The iShares Biotechnology ETF (IBB) gaine
CASI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
CASI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
CASI Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 83.49% HC Wainwright & Co. $12 → $6 Maintains Buy 11/15/2023 266.97% HC Wainwright & Co. $10 →
Casi Pharma Spikes as FDA Clears Clinical Trial for Blood Disorder Therapy
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 d
Express News | CASI Pharmaceuticals Inc: On May 13, 2024 CASI Received a Letter From FDA Indicating That Study May Proceed
Express News | CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug (Ind) Application for Cid-103 in Immune Thrombocytopenia (Itp)
CASI Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | CASI Pharmaceuticals. Inc. : H.c. Wainwright Cuts Target Price to $6 From $12
Express News | CASI Pharmaceuticals Inc Qtrly Shr Loss $0.71
Express News | CASI Pharmaceuticals Q1 Cash & Investments USD 18.2 Million
Express News | CASI Pharmaceuticals Q1 Revenue USD 3.4 Million
Express News | CASI Pharmaceuticals Announces First Quarter 2024 Business and Financial Results
CASI Pharmaceuticals 1Q Loss/Shr 71c >CASI
CASI Pharmaceuticals 1Q Loss/Shr 71c >CASI
Express News | CASI Pharmaceuticals Inc Files for Mixed Shelf of Upto $50 Mln - SEC Filing
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas
On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong I
CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI
CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI
CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute With Juventas Cell Therapy Ltd Prohibiting Juventas From Commercializing CNCT19
On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company ("CASI" or the "Company") announced that, with respect to the Company's previously announced dispute with Juventas
Analysis
Price Target
No Data
